Department of Pharmaceutical Technology, Faculty of Pharmacy, Ege University, Bornova, 35100, Izmir, Turkey.
Drug Deliv. 2011 Aug;18(6):405-14. doi: 10.3109/10717544.2011.570806. Epub 2011 Apr 2.
The aim of this study was to investigate the potential of thiolated matrix tablets for gastroretentive delivery systems. Poly(acrylic acid)-cysteine (PAA-Cys) and chitosan-4-thiobuthylamidine (chitosan-TBA) were evaluated as anionic and cationic thiolated polymers and riboflavin was used as a model drug. Tablets were prepared by direct compression and each formulation was characterized in terms of disintegration, swelling, mucoadhesion, and drug release properties. Thereafter, the gastric residence times of tablets were determined with in vivo study in rats. The resulting PAA-Cys and chitosan-TBA conjugates displayed 172.80 ± 30.33 and 371.11 ± 72.74 µmol free thiol groups, respectively. Disintegration studies demonstrated the stability of thiolated tablets up to 24 h, whereas tablets prepared with unmodified PAA and chitosan disintegrated within a time period of 1 h. Mucoadhesion studies showed that mucoadhesion work of PAA-Cys and chitosan-TBA tablets were 1.341- and 2.139-times higher than unmodified ones. The mucoadhesion times of PAA, PAA-Cys, chitosan, and chitosan-TBA tablets were 1.5 ± 0.5, 21 ± 1, 1 ± 0.5, 17 ± 1 h, respectively. These results confirm the theory that thiol groups react with mucin glycoproteins and form covalent bonds to the mucus layer. Release studies indicated that a controlled release was provided with thiolated tablets up to 24 h. These promising in vitro results of thiolated tablets were proved with in vivo studies. The thiolated tablets showed a gastroretention time up to 6 h, whereas unmodified tablets completely disintegrated within 1 h in rat stomach. Consequently, the study suggests that thiolated matrix tablets might be promising formulations for gastroretentive delivery systems.
本研究旨在探讨巯基化基质片剂作为胃滞留给药系统的潜力。聚(丙烯酸)-半胱氨酸(PAA-Cys)和壳聚糖-4-硫代丁基脒(壳聚糖-TBA)被评估为阴离子和阳离子巯基化聚合物,核黄素被用作模型药物。片剂通过直接压缩制备,并且每种制剂都在崩解、溶胀、粘膜粘附和药物释放特性方面进行了表征。然后,通过在大鼠体内研究来确定片剂的胃滞留时间。所得的 PAA-Cys 和壳聚糖-TBA 缀合物分别显示 172.80 ± 30.33 和 371.11 ± 72.74 µmol 游离巯基。崩解研究表明,巯基化片剂在 24 小时内稳定,而用未改性的 PAA 和壳聚糖制备的片剂在 1 小时内崩解。粘膜粘附研究表明,PAA-Cys 和壳聚糖-TBA 片剂的粘膜粘附功分别比未改性的高 1.341-和 2.139 倍。PAA、PAA-Cys、壳聚糖和壳聚糖-TBA 片剂的粘膜粘附时间分别为 1.5 ± 0.5、21 ± 1、1 ± 0.5、17 ± 1 h。这些结果证实了巯基与粘蛋白糖蛋白反应并与粘液层形成共价键的理论。释放研究表明,巯基化片剂可提供长达 24 小时的控制释放。这些有希望的巯基化片剂的体外结果通过体内研究得到证实。巯基化片剂在胃中的滞留时间可达 6 小时,而未改性片剂在大鼠胃中 1 小时内完全崩解。因此,该研究表明,巯基化基质片剂可能是胃滞留给药系统的有前途的制剂。